134 related articles for article (PubMed ID: 2783975)
1. New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity.
Laguzza BC; Nichols CL; Briggs SL; Cullinan GJ; Johnson DA; Starling JJ; Baker AL; Bumol TF; Corvalan JR
J Med Chem; 1989 Mar; 32(3):548-55. PubMed ID: 2783975
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the monoclonal antibody-Vinca alkaloid immunoconjugate LY203725 (KS1/4-4-desacetylvinblastine-3-carboxhydrazide) in a nude mouse model of human ovarian cancer.
Apelgren LD; Zimmerman DL; Briggs SL; Bumol TF
Cancer Res; 1990 Jun; 50(12):3540-4. PubMed ID: 2340502
[TBL] [Abstract][Full Text] [Related]
3. Chemoimmunoconjugate development for ovarian carcinoma therapy: preclinical studies with vinca alkaloid-monoclonal antibody constructs.
Apelgren LD; Bailey DL; Briggs SL; Barton RL; Guttman-Carlisle D; Koppel GA; Nichols CL; Scott WL; Lindstrom TD; Baker AL
Bioconjug Chem; 1993; 4(2):121-6. PubMed ID: 7873643
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of L/1C2-4-desacetylvinblastine-3-carboxhydrazide immunoconjugate in xenografts.
Johnson DA; Baker AL; Laguzza BC; Fix DV; Gutowski MC
Cancer Res; 1990 Mar; 50(6):1790-4. PubMed ID: 2306731
[TBL] [Abstract][Full Text] [Related]
5. Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice.
Spearman ME; Goodwin RM; Apelgren LD; Bumol TF
J Pharmacol Exp Ther; 1987 May; 241(2):695-703. PubMed ID: 3494841
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and disposition of the KS1/4 monoclonal antibody-desacetylvinblastine hydrazide conjugate LY203725 in rats and monkeys.
Lindstrom TD; Althaus WA; Ruterbories KJ; Kau D
J Pharmacol Exp Ther; 1990 Mar; 252(3):1117-24. PubMed ID: 2319463
[TBL] [Abstract][Full Text] [Related]
7. Disposition of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB (LY256787), in Fischer 344 rats and rhesus monkeys.
Spearman ME; Goodwin RM; Kau D
Drug Metab Dispos; 1987; 15(5):640-7. PubMed ID: 2891480
[TBL] [Abstract][Full Text] [Related]
8. In vivo antitumor activity of a monoclonal antibody-Vinca alkaloid immunoconjugate directed against a solid tumor membrane antigen characterized by heterogeneous expression and noninternalization of antibody-antigen complexes.
Starling JJ; Maciak RS; Law KL; Hinson NA; Briggs SL; Laguzza BC; Johnson DA
Cancer Res; 1991 Jun; 51(11):2965-72. PubMed ID: 2032233
[TBL] [Abstract][Full Text] [Related]
9. In vivo antitumor activity of a panel of four monoclonal antibody-vinca alkaloid immunoconjugates which bind to three distinct epitopes of carcinoembryonic antigen.
Starling JJ; Maciak RS; Hinson NA; Nichols CL; Briggs SL; Laguzza BC; Smith W; Corvalan JR
Bioconjug Chem; 1992; 3(4):315-22. PubMed ID: 1382618
[TBL] [Abstract][Full Text] [Related]
10. KS1/4-DAVLB, a monoclonal antibody-vinca alkaloid conjugate for site-directed therapy of epithelial malignancies.
Bumol TF; Baker AL; Andrews EL; DeHerdt SV; Briggs SL; Spearman ME; Apelgren LD
Targeted Diagn Ther; 1988; 1():55-79. PubMed ID: 2979063
[No Abstract] [Full Text] [Related]
11. The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies.
Petersen BH; DeHerdt SV; Schneck DW; Bumol TF
Cancer Res; 1991 May; 51(9):2286-90. PubMed ID: 2015593
[TBL] [Abstract][Full Text] [Related]
12. In vivo efficacy of monoclonal antibody-drug conjugates of three different subisotypes which bind the human tumor-associated antigen defined by the KS1/4 monoclonal antibody.
Starling JJ; Maciak RS; Hinson NA; Nichols CL; Briggs SL; Laguzza BC
Cancer Immunol Immunother; 1989; 28(3):171-8. PubMed ID: 2784353
[TBL] [Abstract][Full Text] [Related]
13. Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27.
Schrappe M; Bumol TF; Apelgren LD; Briggs SL; Koppel GA; Markowitz DD; Mueller BM; Reisfeld RA
Cancer Res; 1992 Jul; 52(14):3838-44. PubMed ID: 1617657
[TBL] [Abstract][Full Text] [Related]
14. Antitumor xenograft activity with a conjugate of a Vinca derivative and the squamous carcinoma-reactive monoclonal antibody PF1/D.
Johnson DA; Laguzza BC
Cancer Res; 1987 Jun; 47(12):3118-22. PubMed ID: 3495327
[TBL] [Abstract][Full Text] [Related]
15. The effects of formulation and moisture on the stability of a freeze-dried monoclonal antibody-vinca conjugate: a test of the WLF glass transition theory.
Roy ML; Pikal MJ; Rickard EC; Maloney AM
Dev Biol Stand; 1992; 74():323-39; discussion 340. PubMed ID: 1592182
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody 44-3A6 doxorubicin immunoconjugates: comparative in vitro anti-tumor efficacy of different conjugation methods.
Sinkule JA; Rosen ST; Radosevich JA
Tumour Biol; 1991; 12(4):198-206. PubMed ID: 1651554
[TBL] [Abstract][Full Text] [Related]
17. Disposition of a murine monoclonal antibody vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinomas.
Schneck D; Butler F; Dugan W; Littrell D; Petersen B; Bowsher R; DeLong A; Dorrbecker S
Clin Pharmacol Ther; 1990 Jan; 47(1):36-41. PubMed ID: 2295217
[TBL] [Abstract][Full Text] [Related]
18. Intratumour therapy of solid tumours with ricin-antibody conjugates.
Kanellos J; McKenzie IF; Pietersz GA
Immunol Cell Biol; 1989 Apr; 67 ( Pt 2)():89-99. PubMed ID: 2786496
[TBL] [Abstract][Full Text] [Related]
19. Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models.
Meyer DL; Jungheim LN; Law KL; Mikolajczyk SD; Shepherd TA; Mackensen DG; Briggs SL; Starling JJ
Cancer Res; 1993 Sep; 53(17):3956-63. PubMed ID: 8358723
[TBL] [Abstract][Full Text] [Related]
20. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
